Rachman Ilya M Insider Trading Activity

Average Profitability
36.26%
Insider Buys Quantity
5
Insider Buys Sum
$38,893.43
Insider Sells Quantity
0
Insider Sells Sum
$0

Insider Activity of Rachman Ilya M

According to the SEC Form 4 filings, Rachman Ilya M, being in a position of

  1. CEO and Chairman at Immix Biopharma, Inc.,
    оver the last 12 months, has bought 746 shares for $4,976, and sold 0 shares,
    over all time since 2021-12-20, has bought 23324 shares for $53,918, and sold 0 shares.

Biography of Rachman Ilya M

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
 $4,9761100
Sells
 $000

Comparison of Insiders on Amount of Buys and Sells

2025-12-10PurchaseImmix Biopharma, Inc.
IMMX
CEO and Chairman
746
0.0022%
$6.67$4,976+32.84%
2025-09-17PurchaseImmix Biopharma, Inc.
IMMX
CEO and Chairman
2,500
0.0089%
$2.02$5,050+332.14%
2025-06-18PurchaseImmix Biopharma, Inc.
IMMX
CEO and Chairman
2,178
0.0075%
$2.29$4,999+107.53%
2024-06-07PurchaseImmix Biopharma, Inc.
IMMX
CEO and Chairman
2,600
0.0103%
$2.13$5,538-2.96%
2024-06-04PurchaseImmix Biopharma, Inc.
IMMX
CEO and Chairman
3,300
0.0125%
$1.81$5,970+8.84%
2024-05-14PurchaseImmix Biopharma, Inc.
IMMX
CEO and Chairman
4,300
0.0166%
$2.25$9,660-10.45%
2022-11-14PurchaseImmix Biopharma, Inc.
IMMX
CEO and Chairman
5,200
0.0365%
$1.00$5,225+107.28%
2021-12-20PurchaseImmix Biopharma, Inc.
IMMX
CEO and Chairman
2,500
0.1047%
$5.00$12,500-34.77%
Total: 8
Company
About Prismo.proIdeasArticlesPrivacy PolicyTerms of ServiceContact Us
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksStock NewsInsider RatioList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.